Peter J.P. Croucher
Publications by Year
Research Areas
Inflammatory Bowel Disease, Acute Myeloid Leukemia Research, Cancer Genomics and Diagnostics, Helicobacter pylori-related gastroenterology studies, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations(2001)1,091 cited
- → The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease(2002)690 cited
- → Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis(2013)393 cited
- → Evidence for a NOD2 -independent susceptibility locus for inflammatory bowel disease on chromosome 16p(2001)106 cited
- → Study of C-C Chemokine Receptor 2 Alleles in Sarcoidosis, with Emphasis on Family-based Analysis(2005)54 cited
- → Genomic structure, chromosome mapping and expression analysis of the human AVIL gene, and its exclusion as a candidate for locus for inflammatory bowel disease at 12q13–14 (IBD2)(2002)18 cited
- → Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia(2023)9 cited
- → Abstract 2019: Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)(2020)4 cited
- → Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)(2019)2 cited
- → Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.(2013)1 cited